A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
← catalyst calendarNCT07675811 · readout in 1,016 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
570estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | actual | When the study began enrolling |
| Primary completion | 2029-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergic Conjunctivitis
Interventions
- Drug: REGN-2Cat — also filed as REGN1908-REGN1909
- Drug: Freneslerbart — also filed as REGN1908
- Drug: Mevonlerbart — also filed as REGN1909
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFOcular itch score in participants receiving REGN-2Cat as compared to placebo
measured At day 8, post-Conjunctival Allergen Challenge (CAC)
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed